Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than 35.8% in afternoon trading on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
SMCI | Super Micro Computer, Inc. | October 29, 2024 | Join |
ZI | ZoomInfo Technologies Inc. | November 04, 2024 | Join |
WBTN | WEBTOON Entertainment Inc. | November 04, 2024 | Join |
GTLB | GitLab Inc. | November 04, 2024 | Join |
GTLB | GitLab Inc. | November 04, 2024 | Join |
AGEN | Agenus Inc. | November 05, 2024 | Join |
NFE | New Fortress Energy Inc. | November 18, 2024 | Join |
MGX | Metagenomi, Inc. | November 25, 2024 | Join |
BMBL | Bumble Inc. | November 25, 2024 | Join |
UPS | United Parcel Service, Inc. | December 09, 2024 | Join |
EW | Edwards Lifesciences Corporation | December 13, 2024 | Join |
TD | The Toronto-Dominion Bank | December 23, 2024 | Join |